IFIH1 and dermatomyositis: Differences in the clinical characteristics and serological indices were also examined between anti-MDA5 antibody-positive and anti-MDA5 antibody-negative patients with DM, those with CADM, and those with CDM to evaluate the impact of anti-MDA5 antibodies on patients with DM.